Score Breakdown
Dilution Forecast
Market Data
Source-Backed Evidence Depth
This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.
| Field | Current Value | Basis |
|---|---|---|
| DilutionScore | 40/100 | DilutionWatch score record |
| Shares Outstanding | 111.51M | Verified float table or market cache |
| Public Float | 21.28M | Verified float table or market cache |
| Market Cap | $765.52M | Market data cache |
| Cash Runway | Not applicable / unavailable | DilutionWatch score inputs |
| Shelf Capacity | None in current score inputs | SEC-derived dilution fields |
| ATM Capacity | None in current score inputs | SEC-derived dilution fields |
| Outstanding Warrants | None in current score inputs | SEC-derived dilution fields |
Recent source-backed SEC insight records available on this page: 7.
Recent SEC source mix: 4 1, 8-K 2, FORM 4 2, XBRL 2.
The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.
Institutional Holdings
Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.
Short Interest
Recent SEC Activity
Recent News
Factual GYRE Dilution Snapshot
Gyre Therapeutics, Inc. (GYRE) has a DilutionScore of 40/100, rated Medium dilution risk. Score date: October 13, 2026.
- Recent SEC activity tracked for GYRE: xbrl on 2026-08-07; Form 4 on 2026-08-03; Form 4 on 2026-08-03.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
DilutionScore History — Last 90 Days
GYRE's DilutionScore is currently 40/100 (Medium risk), with 3 score changes tracked over 89 days. The score improved from 38/100 (Medium risk).
| Period | Score | Risk Level | Duration |
|---|---|---|---|
| Sep 30 – Oct 13, 2026 | 40/100 | MEDIUM | 14 days |
| Aug 22 – Sep 29, 2026 | 38/100 | MEDIUM | 39 days |
| Aug 14 – Aug 21, 2026 | 42/100 | MEDIUM | 7 days |
| Jul 16 – Aug 13, 2026 | 35/100 | MEDIUM | 29 days |
Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.
Share Dilution History
GYRE shares outstanding have increased 0.7% from 96.33M (Mar 2026) to 97.03M (May 2026). Each increase represents potential dilution to existing shareholders.
| Date | Shares Outstanding | Public Float | Change |
|---|---|---|---|
| May 15, 2026 | 97.03M | 21.28M | ▼ 16.03% |
| May 11, 2026 | 96.99M | 25.34M | ▲ 0.04% |
| May 10, 2026 | 96.99M | 25.33M | ▲ 1.03% |
| May 09, 2026 | 96.99M | 25.07M | ▲ 19.70% |
| Mar 17, 2026 | 96.33M | 20.95M | ▲ 1.59% |
| Mar 15, 2026 | 96.33M | 20.62M | ▲ 0.47% |
Share counts sourced from verified regulatory filings. Increases indicate dilution events.
Related Stocks — MEDIUM Risk
Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.